The Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), has been awarded a $1,576,423 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This federal grant, awarded on August 1, 2024, will support research to mitigate therapy resistance by combining CDK4/6 and PI3K/mTOR inhibition in pediatric and adolescent/young adult (AYA) osteosarcoma. The research project aims to develop novel therapeutic approaches to address this challenge in treating osteosarcoma, a rare and aggressive form of bone cancer. As a leading research institution, IU Indianapolis will leverage its expertise in biomedical research, clinical trials, and innovative therapy development to advance this important work over the three-year project period, with a planned completion date of July 31, 2027.
Generated 1/28/25, 7:42 AM